Becoming a Psychedelic User: Reflections on Howard Becker and the (Future) Sociology of Psychedelics
Sociology Compass August 1, 2025 DOI: 10.1111/soc4.70096 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Keywords | Anthropology Psychoanalysis Epistemology |
| Citations | 1 |
| Key points | Argues that Becker's sociological framework can inform the study of contemporary psychedelic retreats as drug-using subcultures. |
Abstract
ABSTRACT Howard Becker's early research on drug use—from examining how one becomes a marijuana user to analyzing the social contexts of LSD experiences—was innovative and radical for its time. Today, the unfolding “second wave” of psychedelia continues to generate new insights into how to best curate the social contexts of psychedelic use and hone the experience for transformative and therapeutic outcomes. Despite the promising results of myriad clinical studies of psychedelic therapeutic efficacy, sociological theories and methods of naturalistic psychedelic use are largely lacking at this stage. In this paper, I revisit the sociology of drug use and drug experiences Becker provided 70 years ago to bring attention to how scholars today can contribute social scientific research to psychedelic science, culture, and medicine. After a review of Becker's work on drug use and its impact, I analyze a contemporary form of naturalistic, collective psychedelic use in retreat settings, viewing them as what Becker described as a “drug‐using subculture,” or a space where individuals “learn to get high.” In analyzing the sociocultural phenomena that take place on psychedelic retreats, the objective of this paper is to draw on Becker's insights to inspire ideas and chart a path forward for a renewed 21st‐century sociology of psychedelics.
Citations in the library
Cites 59
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Journal of Psychopharmacology September 11, 2014
and 54 more in the library